Statin Immune Study

Drug Intolerance Clinical Trial

— ImmunoStat  

Official title:

Impact of LILRB5 Genotype on Immune Response to Atorvastatin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02984293
• Other study ID #: 2016CV05
• Secondary ID: 16/ES/0128
• Status: Completed
• Phase: Phase 4
• Start date: April 17, 2017
• Est. completion date: November 3, 2017

Study information

• Verified date: March 2018
• Source: University of Dundee
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Statins are widely used drugs to treat hypercholesterolaemia. In general, they are very safe drugs. However, up to one third of statin users can experience muscle symptoms, which are most commonly mild without any conventional laboratory signs of muscle damage. However, these muscle symptoms can often lead to poor compliance to the cholesterol-lowering therapy, reducing its effectiveness. Recent data has highlighted the potential role of immune system in development of statin-induced muscle pain. Variation in the LILRB5 gene has been associated with statin intolerance. We aim to investigate the impact of LILRB5 genetic variability in tolerability and immune response to atorvastatin in healthy volunteers.

The study is being undertaken at the Tayside Institute for Cardiovascular Research (TICR) in Ninewells Hospital, Dundee. We will recruit participants who have donated a sample to GoSHARE study. The participants will be healthy, and recruited according to their genotype of LILRB5 (information available from GoSHARE). The volunteers will then enter a randomised cross-over study with two treatment periods. During treatment period one, all participants will be commenced on atorvastatin or placebo (a dummy drug). Before and at the end of the treatment period, blood and urine samples will be taken and a muscle symptoms questionnaire will be completed to assess the tolerability and immune response to the study drug exposure. After four weeks, the study drug is stopped for a washout period of three weeks before cross-over commences. Thereafter, during treatment period two, the alternate study drug will be started, and tolerability will be assessed similar to that in period one. The study will last approximately 11 weeks. The volunteers have a total of 5 visits to the TICR.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: November 3, 2017
• Est. primary completion date: November 3, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 69 Years

Eligibility

Inclusion Criteria:

• Age 40-69 years

• Statin-naïve

• White European

• Healthy

• Acceptable laboratory test results

Exclusion Criteria:

• Significant disease

• Regular drug therapy

• Recent involvement (<30 days) in a CTIMP

• Inability/unwillingness to comply with the protocol

• Carry the rare variant of the CKM polymorphism rs11559024

• Unable to consent

• Woman of childbearing potential (i.e. premenopausal female capable of becoming pregnant)

Related Conditions & MeSH terms

• Drug Intolerance

Intervention

Drug:
• Atorvastatin
Atorvastatin 80 mg once daily for 28 days.
• Placebo
Placebo once daily for 28 days.

Locations

Country	Name	City	State
United Kingdom	University of Dundee	Dundee

Sponsors (2)

Lead Sponsor	Collaborator
University of Dundee	NHS Tayside

Country where clinical trial is conducted

United Kingdom, 

References & Publications (2)

Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, Carr DF, Bloch KM, Fahy J, Hanson A, Yue QY, Wadelius M, Maitland-van Der Zee AH, Voora D, Psaty BM, Palmer CN, Pirmohamed M. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014 Oct;96(4):470-6. doi: 10.1038/clpt.2014.121. Epub 2014 Jun 4. — View Citation

Dubé MP, Zetler R, Barhdadi A, Brown AM, Mongrain I, Normand V, Laplante N, Asselin G, Zada YF, Provost S, Bergeron J, Kouz S, Dufour R, Diaz A, de Denus S, Turgeon J, Rhéaume E, Phillips MS, Tardif JC. CKM and LILRB5 are associated with serum levels of creatine kinase. Circ Cardiovasc Genet. 2014 Dec;7(6):880-6. doi: 10.1161/CIRCGENETICS.113.000395. Epub 2014 Sep 11. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome will be the change in CK levels at the end of the treatment from baseline in both treatment periods.		Measured at baseline (day 0) and day 29 of both treatment periods.

External Links

•   Project website